Janus Henderson Group PLC Boosts Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)

Janus Henderson Group PLC grew its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,380,382 shares of the biotechnology company's stock after buying an additional 193,688 shares during the quarter. Janus Henderson Group PLC owned 7.22% of Ascendis Pharma A/S worth $602,910,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in ASND. Wilmington Savings Fund Society FSB purchased a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth $30,000. Jones Financial Companies Lllp boosted its position in Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 197 shares in the last quarter. Blue Trust Inc. boosted its position in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 328 shares in the last quarter. GAMMA Investing LLC boosted its position in Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 214 shares in the last quarter. Finally, Quarry LP bought a new stake in Ascendis Pharma A/S during the fourth quarter valued at about $96,000.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND traded up $0.06 during trading on Friday, reaching $157.60. The stock had a trading volume of 501,190 shares, compared to its average volume of 494,419. The business has a fifty day moving average price of $156.91 and a 200-day moving average price of $142.15. The stock has a market cap of $9.61 billion, a PE ratio of -22.20 and a beta of 0.41. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analysts' expectations of $98.56 million. Sell-side analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on ASND. Wedbush increased their price target on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Morgan Stanley upgraded Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $180.00 to $250.00 in a research note on Monday, May 5th. The Goldman Sachs Group increased their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Royal Bank of Canada increased their price target on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Finally, Evercore ISI increased their price target on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $216.07.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.